STATE STREET CORP - ALLOGENE THERAPEUTICS INC ownership

ALLOGENE THERAPEUTICS INC's ticker is ALLO and the CUSIP is 019770106. A total of 154 filers reported holding ALLOGENE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 7.07 and the average weighting 0.1%.

Quarter-by-quarter ownership
STATE STREET CORP ownership history of ALLOGENE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$26,002,245
-38.3%
8,202,601
-3.3%
0.00%
-50.0%
Q2 2023$42,139,442
+3.9%
8,478,761
+3.3%
0.00%0.0%
Q1 2023$40,562,706
-64.8%
8,211,074
-55.2%
0.00%
-33.3%
Q4 2022$115,313,412
+59.8%
18,332,816
+174.4%
0.00%
-40.0%
Q3 2022$72,147,000
+11.9%
6,680,297
+18.1%
0.01%
+25.0%
Q2 2022$64,459,000
-10.2%
5,654,324
-28.2%
0.00%0.0%
Q1 2022$71,765,000
+9.0%
7,877,648
+78.5%
0.00%
+33.3%
Q4 2021$65,843,000
-27.1%
4,413,045
+25.6%
0.00%
-40.0%
Q3 2021$90,292,000
+15.2%
3,513,316
+16.9%
0.01%
+25.0%
Q2 2021$78,368,000
-4.9%
3,004,900
+28.8%
0.00%
-20.0%
Q1 2021$82,383,000
-3.2%
2,333,796
-30.8%
0.01%0.0%
Q4 2020$85,146,000
-11.9%
3,373,461
+31.6%
0.01%
-28.6%
Q3 2020$96,675,000
-0.0%
2,563,632
+13.5%
0.01%0.0%
Q2 2020$96,679,000
+193.5%
2,257,791
+33.3%
0.01%
+133.3%
Q1 2020$32,936,000
-24.5%
1,694,216
+0.9%
0.00%0.0%
Q4 2019$43,632,000
+19.1%
1,679,450
+25.0%
0.00%0.0%
Q3 2019$36,625,000
-14.9%
1,343,795
-16.2%
0.00%0.0%
Q2 2019$43,046,000
+32.2%
1,603,221
+42.4%
0.00%0.0%
Q1 2019$32,549,000
+240.6%
1,125,859
+217.3%
0.00%
+200.0%
Q4 2018$9,555,000354,7920.00%
Other shareholders
ALLOGENE THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
Vida Ventures Advisors, LLC 1,798,163$16,381,0009.53%
Wildcat Capital Management, LLC 2,128,370$19,389,0004.96%
TPG GP A, LLC 18,716,306$170,506,0002.11%
Pier Capital, LLC 746,669$6,802,0000.87%
Coastal Bridge Advisors, LLC 401,929$3,662,0000.84%
HARBOR CAPITAL ADVISORS, INC. 92,755$845,0000.40%
Lombard Odier Asset Management (Switzerland) SA 501,219$4,566,0000.36%
Navalign, LLC 74,271$623,0000.26%
PDT Partners, LLC 241,592$2,201,0000.19%
GSA CAPITAL PARTNERS LLP 148,804$1,356,0000.18%
View complete list of ALLOGENE THERAPEUTICS INC shareholders